
Francis Farraye
Mayo Clinic
Francis A. Farraye, MD, MSc is Director of the Inflammatory Bowel Disease Center in the Division of Gastroenterology and Hepatology and Professor of Medicine at the Mayo Clinic in Jacksonville, FL. He received his MD from Albert Einstein College of Medicine in New York. He completed an internal medicine residency and gastroenterology fellowship at the Beth Israel Hospital in Boston and a Master's Degree in Epidemiology from the Harvard School of Public Health. Dr. Farraye has an active academic clinical practice managing patients with Inflammatory Bowel Disease. A frequent speaker and invited lecturer on topics on the diagnosis and management of inflammatory bowel disease, Dr. Farraye has authored or co-authored over 600 original scientific manuscripts, chapters, reviews, and abstracts. He is the series editor for the text Curbside Consultation in Gastroenterology and co-wrote the text, Curbside Consultation in Inflammatory Bowel Disease and Gastrointestinal Emergencies. His newest book for patients is Mayo Clinic on Crohn's Disease and Ulcerative Colitis. He is the Editor in Chief for Inflammatory Bowel Disease Journal Scan published weekly by the ASGE. Dr. Farraye is a Fellow in the AGA, ASGE, Crohns and Colitis Foundation, and a Master of the American College of Gastroenterology. He has served on numerous national and international committees and presently is the Vice Chair of the IBD committee for the World Gastroenterology Organization. The New England Crohn's and Colitis Foundation named Dr. Farraye Humanitarian of the Year in 2003 and in 2020, Dr. Farraye was a recipient of the Lifetime Achievement Award from the New England Crohn's and Colitis Foundation.
Appearances
- DateMay 7, 2023SOCIETY: ASGE
Speaker
Presenter
Mayo Clinic - DateMay 19, 2024Patients with inflammatory bowel disease (IBD) are at an increased risk for vaccine-preventable diseases, such as herpes zoster (HZ). The aim of this study was to determine whether complications of HZ are more frequent in patients with IBD than in non-IBD controls…
Presenter
University of WisconsinSpeakers
University of California San DiegoMayo Clinic in FloridaMayo Clinic - DateMay 21, 2024BACKGROUND: The primary objective of the VIVID-1 trial (NCT03926130) was to demonstrate efficacy and safety of mirikizumab (miri), a p19-directed anti-IL-23 antibody, compared to placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease…
Presenter
Speakers
Mayo ClinicCharité - Universitätsmedizin BerlinWestern University - DateMay 3, 2025
Speaker
Mayo Clinic